Press coverage about The Medicines (NASDAQ:MDCO) has been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. The Medicines earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.9621802181992 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- MDCO: License Agreement For IONSYS Terminated (investing.com)
- Matinas BioPharma Appoints Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A., to Board of Directors (feeds.benzinga.com)
- Medicines Company Investor Day January 23 (seekingalpha.com)
- The Medicines Company to Host Investor Day on January 23, 2018 (finance.yahoo.com)
- This Morning’s Technical Outlook on Generic Drugs Stocks — Versartis, Akorn, Rigel Pharma, and Medicines (prnewswire.com)
A number of research firms have weighed in on MDCO. Citigroup raised shares of The Medicines from a “sell” rating to an “outperform” rating in a report on Thursday, November 30th. Oppenheimer set a $50.00 price objective on shares of The Medicines and gave the stock a “hold” rating in a report on Thursday, October 26th. Jefferies Group reissued a “buy” rating and set a $54.00 price objective on shares of The Medicines in a report on Thursday, October 26th. ValuEngine raised shares of The Medicines from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Finally, Chardan Capital restated a “buy” rating and set a $85.00 target price on shares of The Medicines in a research report on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. The Medicines currently has an average rating of “Buy” and an average target price of $53.67.
The Medicines (MDCO) opened at $27.25 on Friday. The company has a debt-to-equity ratio of 3.42, a quick ratio of 1.79 and a current ratio of 2.31. The Medicines has a 1 year low of $25.40 and a 1 year high of $55.95.
The Medicines (NASDAQ:MDCO) last announced its earnings results on Wednesday, October 25th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.95. The business had revenue of $16.87 million for the quarter, compared to analyst estimates of $26.06 million. The Medicines had a negative net margin of 767.94% and a negative return on equity of 174.68%. The company’s revenue for the quarter was down 55.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.64) earnings per share. sell-side analysts expect that The Medicines will post -8.86 earnings per share for the current year.
In other The Medicines news, insider Fredric N. Eshelman bought 200,000 shares of the stock in a transaction dated Friday, December 8th. The shares were acquired at an average cost of $26.56 per share, for a total transaction of $5,312,000.00. Following the completion of the transaction, the insider now owns 1,028,383 shares in the company, valued at approximately $27,313,852.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Alexander J. Denner bought 170,000 shares of the stock in a transaction dated Wednesday, November 29th. The shares were acquired at an average price of $30.03 per share, for a total transaction of $5,105,100.00. Following the completion of the transaction, the director now owns 6,663 shares of the company’s stock, valued at approximately $200,089.89. The disclosure for this purchase can be found here. Company insiders own 8.22% of the company’s stock.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.